The real-world use and effectiveness of avacopan in routine practice for the treatment of ANCA vasculitis. First experiences in Spain.

Autor: Draibe J; Department of Nephrology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain., Espigol-Frigolé G; Department of Autoimmune Diseases, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain., Cid MC; Department of Autoimmune Diseases, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain. Member of the European Reference Network, RITA., Prados MC; Department of Nephrology, Torrecárdenas Hospital, Almería, Spain., Guillén E; Department of Nephrology, Hospital Clinic, Barcelona, Spain., Villacorta J; Department of Nephrology, Ramón y Cajal Hospital, Madrid, Spain., Vega C; Department of Nephrology, La Paz Hospital, Madrid, Spain., Martins J; Department of Nephrology, Getafe Hospital, Madrid, Spain., daSilva I; Department of Nephrology, Hospital Can Ruti, Barcelona, Spain., Martin-Gomez MA; Department of Nephrology, Hospital Poniente, Almeria, Spain., Huerta A; Department of Nephrology, Puerta de Hierro Hospital, Madrid, Spain., Martinez-Valenzuela L; Department of Nephrology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain., Morales E; Department of Nephrology, Instituto de Investigación Sanitaria Hospital 12 de octubre(imas12), Madrid, Spain. Medicine Department, Complutense University of Madrid, Spain.

Publikováno v: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2024 Oct 01. Date of Electronic Publication: 2024 Oct 01.

Early Macrophage Infiltration and Sustained Inflammation in Kidneys From Deceased Donors Are Associated With Long-Term Renal Function

Autor: Guillén-Gómez, E., Dasilva, I., Silva, I., Arce, Y., Facundo, C., Ars, E., Breda, A., Ortiz, A., Guirado, L., Ballarín, J.A., Díaz-Encarnación, M.M. ^*

Publikováno v: In American Journal of Transplantation March 2017 17(3):734-744

Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy.

Autor: Lee H; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia., Ferguson AL; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.; Centenary Institute, The University of Sydney, Sydney, New South Wales, Australia.; Infection, Immunity and Inflammation theme, School of Medical Sciences, The Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia., Quek C; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia., Vergara IA; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia., Pires daSilva I; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.; Westmead and Blacktown Hospitals, Sydney, New South Wales, Australia., Allen R; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia., Gide TN; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia., Conway JW; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia., Koufariotis LT; QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Hayward NK; QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Waddell N; QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Carlino MS; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Royal North Shore Hospital, Sydney, New South Wales, Australia., Menzies AM; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Royal North Shore Hospital, Sydney, New South Wales, Australia.; Mater Hospital, North Sydney, New South Wales, Australia., Saw RPM; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Mater Hospital, North Sydney, New South Wales, Australia.; Royal Prince Alfred Hospital, Sydney, New South Wales, Australia., Shklovskaya E; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia., Rizos H; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia., Lo S; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia., Scolyer RA; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.; Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.; NSW Health Pathology, Sydney, New South Wales, Australia., Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.; Royal North Shore Hospital, Sydney, New South Wales, Australia.; Mater Hospital, North Sydney, New South Wales, Australia., Palendira U; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.; Centenary Institute, The University of Sydney, Sydney, New South Wales, Australia.; Infection, Immunity and Inflammation theme, School of Medical Sciences, The Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia., Wilmott JS; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Jul 05; Vol. 29 (13), pp. 2513-2524.

Osteoporosis, bone mineral density and CKD-MBD (II): Therapeutic implications

Autor: Bover J, Ureña-Torres P, Laiz Alonso AM, Torregrosa JV, Rodríguez-García M, Castro-Alonso C, Górriz JL, Benito S, López-Báez V, Lloret Cora MJ, Cigarrán S, DaSilva I, Sánchez-Bayá M, Mateu Escudero S, Guirado L, Cannata-Andía J

Publikováno v: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
NEFROLOGIA
r-FISABIO. Repositorio Institucional de Producción Científica

Osteoporosis (OP) and chronic kidney disease (CKD) both independently affect bone health. A significant number of patients with CKD have decreased bone mineral density (BMD), are at high risk of fragility fractures and have an increased morbidity and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::a34f3e8153417e1f275dfd45429bdee2
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=2860

Osteoporosis, bone mineral density and CKD-MBD complex (I): Diagnostic considerations

Autor: Bover J, Ureña-Torres P, Torregrosa JV, Rodríguez-García M, Castro-Alonso C, Górriz JL, Laiz Alonso AM, Cigarrán S, Benito S, López-Báez V, Lloret Cora MJ, daSilva I, Cannata-Andía J

Publikováno v: NEFROLOGIA
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)

Osteoporosis (OP) and chronic kidney disease (CKD) independently influence bone and cardiovascular health. A considerable number of patients with CKD, especially those with stages 3a to 5D, have a significantly reduced bone mineral density leading to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::a2e3e5f4b2b446246b90f16504e236ac
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=3201